This prospective randomized placebo-controlled double blind clinical trial will conducted in
Ain Shams University maternity Hospital including 120 women diagnosed with clomiphene citrate
resistant polycystic ovary syndrome. After laparoscopic ovarian drilling, they will be
randomized to either receiving 50 mg oral clomiphene citrate twice daily and oral NAC 1,200
mg/day for 5 days starting from cycle day 2 to cycle day 6 (group 1 = 60 patients) or
clomiphene citrate only (group 2 = 60 patients). The primary outcome will be biochemical
pregnancy rate, secondary outcomes include Clinical pregnancy rate, ovulation rate, live
birth rate, number of follicles ≥ 18 mm and endometrial thickness at triggering ovulation,
mid- luteal sub-endometrial blood flow indices, and incidence of side effects.